ACE-IPF Study (AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis)
Study Status
Closed to Enrollment
Study Description
The ACE-IPF study tests the safety and effectiveness of the drug warfarin in patients with Idiopathic Pulmonary Fibrosis (IPF). Study volunteers will be randomized to warfarin or placebo. Study visits will occur at baseline (study entry), and weeks 1, 16, 32, 48 and 54. Volunteers will be reimbursed a maximum of $250 per visit for study travel expenses relating to mileage, commercial air or ground travel, hotel costs, meals and parking fees after providing travel receipts to the study coordinator.
Click here to visit our IPF blog.
Disease Status and/or Stage
Idiopathic Pulmonary Fibrosis (IPF)
Sponsor
IPFnet/NIH
Key Eligibility
- Men and women ages 35–80
- Diagnosis of IPF
- Progression of disease despite conventional therapy (standard of care treatment)
- More detailed eligibility requirements will be discussed with you when contact the study team
Principal Investigator
Contact
- Ida Cao
- 646-962-4508
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
